5 research outputs found
Place des anticorps anti-p53 dans la prise en charge des cancers colo-rectaux
CLERMONT FD-BCIU-Santé (631132104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF
Les tumeurs intracanalaires papillaires et mucineuses du pancréas (à propos d'une série de 47 cas)
Les tumeurs intracanalaires papillaires et mucineuses du pancréas (TIPMP) sont des tumeurs à potentiel dégénératif dont la fréquence de diagnostic est en augmentation. La prise en charge précoce permet un meilleur pronostic que celui de l'adénocarcinome primitif du pancréas. Le but de cette étude est de rapporter les résultats de notre équipe sur une série rétrospective de 47 patients dont 19 ont été opérés. A partir de notre propre expérience, et après une revue de la littérature, nous proposons une conduite à tenir pour la prise en charge des TIPMP.CLERMONT FD-BCIU-Santé (631132104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF
RĂ©interventions pour cure de reflux gastro-oesophagien (Ă propos de 48 cas)
CLERMONT FD-BCIU-Santé (631132104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF
Les Liposarcomes rétropéritonéaux (revue de la littérature)
CLERMONT FD-BCIU-Santé (631132104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF
Safety and long-term outcome of a new concept for surgical adhesion-reduction strategies (Prevadh): a prospective, multicenter study.
International audienceBACKGROUND/AIMS: No agent has been consistently effective in preventing formation of peritoneal adhesions and postoperative bowel obstruction after abdominal surgery. The aim of this prospective multicenter study was to assess clinical safety and efficiency of a new adhesion-reduction barrier METHODOLOGY: Between September 2000 and April 2001, Prevadh was used in 78 patients. Operative procedures included 25 hepatic resections, 7 cholecystectomies, 32 colonic resections, 7 protectomies, 3 colostomy or recovery of continuity, 1 gynaecologic surgery and 3 others. Eleven patients were operated on by laparoscopy and 67 by laparotomy. RESULTS: The overall incidence of abscesses and wound complications was 2.4% and 9% respectively. After a mean follow-up of 36 months (range: 4-51 months), no patients experienced adverse events related to the adhesion barrier. Surgical reoperative procedures were performed in 10 patients for unrelated causes and no bowel obstruction occurred within the protected area. CONCLUSIONS: This study confirmed the safety of Prevadh adhesion barrier and suggested that this resorbable barrier might provide prevention from adhesion formation on peritoneal injured surfaces. However, a large randomized controlled trial remains necessary to prove the real effectiveness of adhesion barriers on clinical long-term outcome